Equities analysts expect Insmed Incorporated (NASDAQ:INSM) to post earnings per share of ($0.67) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Insmed’s earnings, with estimates ranging from ($0.76) to ($0.59). Insmed posted earnings of ($1.10) per share during the same quarter last year, which would suggest a positive year over year growth rate of 39.1%. The company is scheduled to report its next quarterly earnings results on Thursday, February 22nd.
On average, analysts expect that Insmed will report full year earnings of ($2.67) per share for the current year, with EPS estimates ranging from ($2.78) to ($2.59). For the next financial year, analysts expect that the company will post earnings of ($2.41) per share, with EPS estimates ranging from ($3.60) to ($1.23). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that follow Insmed.
Several research analysts recently issued reports on INSM shares. Zacks Investment Research raised shares of Insmed from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a research report on Wednesday, January 17th. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Insmed in a research report on Thursday, January 4th. Cowen reissued a “buy” rating and issued a $54.00 price target on shares of Insmed in a research report on Friday, November 3rd. BidaskClub raised shares of Insmed from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Finally, ValuEngine raised shares of Insmed from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $36.67.
Several hedge funds and other institutional investors have recently bought and sold shares of INSM. Alliancebernstein L.P. increased its holdings in shares of Insmed by 4.4% during the second quarter. Alliancebernstein L.P. now owns 90,700 shares of the biopharmaceutical company’s stock worth $1,556,000 after buying an additional 3,800 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of Insmed by 4.9% during the second quarter. Teachers Advisors LLC now owns 193,807 shares of the biopharmaceutical company’s stock worth $3,326,000 after buying an additional 9,014 shares in the last quarter. TIAA CREF Investment Management LLC increased its holdings in shares of Insmed by 0.9% during the second quarter. TIAA CREF Investment Management LLC now owns 213,525 shares of the biopharmaceutical company’s stock worth $3,664,000 after buying an additional 1,857 shares in the last quarter. New York State Common Retirement Fund increased its holdings in shares of Insmed by 20.8% during the second quarter. New York State Common Retirement Fund now owns 81,044 shares of the biopharmaceutical company’s stock worth $1,391,000 after buying an additional 13,943 shares in the last quarter. Finally, UBS Asset Management Americas Inc. acquired a new stake in shares of Insmed during the second quarter worth approximately $187,000. 93.43% of the stock is owned by institutional investors.
Insmed (NASDAQ:INSM) traded up $0.16 during trading hours on Friday, reaching $24.09. 736,200 shares of the company traded hands, compared to its average volume of 932,805. Insmed has a 52-week low of $11.49 and a 52-week high of $33.94. The company has a debt-to-equity ratio of 0.13, a current ratio of 15.21 and a quick ratio of 15.21.
WARNING: This article was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/14/insmed-incorporated-insm-expected-to-announce-earnings-of-0-67-per-share.html.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Get a free copy of the Zacks research report on Insmed (INSM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.